cancer usually occurs in older men (older than 50). It is the second most
common cancer globally accounting for 15% of cancers in men. Prostate cancer
presents a burden on the healthcare system because of its high rate of
incidence. Men diagnosed with early-stage, localized prostate cancer have a
good chance of cure and recovery while men diagnosed with advanced
castration-resistant prostate cancer (CRPC) have little chances of cure.
Since 90% of all
are detected in the local
and regional areas at an early stage, almost 100% of men diagnosed at this
stage will remain cancer-free after five years. Prostate cancer is treated with
surgery, radiation therapy, hormone therapy and chemotherapy.
Market Forecast for Global Treatment Value by GlobalData
Owing to the high incidence of prostate
cancer among men, the global market size and value for its treatment is high.
According to a
report released in April 2015 by GlobalData (a research and consulting firm),
the addition of new therapies and pipelined drugs for the treatment of CRPC
will increase the size of the prostate cancer market by three-fold in nine
major pharmaceutical markets (9MM): USA, France, Germany, Italy, Spain, UK,
Japan, Brazil and Canada.
report published by GlobalData on 30 April 2015 indicates that the prostate
cancer treatment market value will treble by $8.2 billion by 2023. The global
treatment market value was $2.6 billion in 2013. This increase is expected
across the 9MM.
increase in market value is driven by a rapidly aging population, the
anticipated introduction of nine, new, strategically priced therapies by 2023
and the anticipated label extensions for Zytiga and Xtandi in the treatment of
hormone-sensitive prostate cancer. Zytiga (Abiraterone Acetate) is made by
Centocor Ortho Biotech, Inc. and received FDA approval in December 2012. Zytiga
is approved for use with prednisone for metastatic CRPC before beginning
chemotherapy. Xtandi (Enzalutamide), made by Medivation, is an anti-androgen
used to treat men whose prostate cancer no longer responds to surgery or other
treatment that lowers testosterone.
Raksha Mudbhary, PhD, GlobalData's Senior Analyst covering oncology, Japan and
Brazil will record the most impressive growth in the forecast period due to
high incidence of prostate cancer and introduction of several branded drugs for
treating CRPC. However, the analyst believes that the primary driver of market
growth in the 9MM will be due to the label extension of Xtandi.
Mudbhary says that
Key Opinion Leaders on the prostate cancer treatment market have been
favourably impressed with Xtandi's safety and efficacy and it is believed that
this drug will be the market leader in this line by 2016.
forecasts that Xtandi sales will increase to $3.8 billion by 2023. This amounts
to an impressive 46% of the total branded drug sales in the prostate cancer
overall positive outlook in growth forecast, some factors may limit growth like
the probable loss of patent protection for Zytiga, which was the leading prostate cancer drug
Mudbhary explains, "Zytiga is anticipated to
lose key US patent protection in December 2016. Although there is some
uncertainty regarding the timing of Zytiga generics entering the US market, the
resulting loss of branded sales will restrict growth during the latter part of
the forecast period."